Curaleaf Holdings (CURLF) Free Cash Flow (2019 - 2024)
Curaleaf Holdings (CURLF) posted quarterly Free Cash Flow of -$32.6 million for Q4 2024, up 13.96% year-on-year from -$28.6 million in Q1 2024, and down 146.52% on a QoQ basis from $70.2 million in Q3 2024.
Curaleaf Holdings (CURLF) Free Cash Flow (2019 - 2024) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Free Cash Flow for 6 consecutive years, with -$32.6 million the latest figure, recorded in Q4 2024.
- Quarterly Free Cash Flow rose 13.96% year-over-year to -$32.6 million in Q4 2024, while the trailing twelve-month figure through Sep 2025 was -$32.6 million (down 130.98% YoY) and the FY2025 annual result came in at $134.9 million, down 9.09% from the prior year.
- Free Cash Flow fell to -$32.6 million in Q4 2024 per CURLF's latest filing, from $70.2 million in the prior quarter.
- Over the last five years, Free Cash Flow for CURLF reached as high as $43.8 billion in Q1 2024 and fell as low as -$43.7 billion in Q2 2024.
- A 5-year average of $3.3 million and a median of $22.4 million in 2020 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2020 — Free Cash Flow jumped 1404672.21% — and 2023, when it sank 21301.34%.
- Year by year, Free Cash Flow stood at -$177.3 million in 2020, then surged by 113.4% to $23.8 million in 2021, then sank by 967.91% to -$206.2 million in 2022, then surged by 81.6% to -$37.9 million in 2023, then increased by 13.96% to -$32.6 million in 2024.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$32.6 million, $70.2 million, and -$43.7 billion for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -208.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 291.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -373.37 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 363.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 348.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 144.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -38.00 Mn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -32.64 Mn |
| Dec 31, 2024 | -32.64 Mn |
| Sep 30, 2024 | 70.16 Mn |
| Sep 30, 2024 | 70.16 Mn |
| Jun 30, 2024 | -43.70 Bn |
| Jun 30, 2024 | -43.70 Bn |
| Mar 31, 2024 | 43.78 Bn |
| Mar 31, 2024 | 43.78 Bn |
| Dec 31, 2023 | -37.94 Mn |
| Dec 31, 2023 | -37.94 Mn |
| Sep 30, 2023 | 62.18 Mn |
| Sep 30, 2023 | 62.18 Mn |
| Jun 30, 2023 | -7.88 Bn |
| Jun 30, 2023 | -7.88 Bn |
| Mar 31, 2023 | 7.90 Bn |
| Mar 31, 2023 | 7.90 Bn |
| Dec 31, 2022 | -206.21 Mn |
| Dec 31, 2022 | -206.21 Mn |
| Sep 30, 2022 | 43.98 Mn |
| Sep 30, 2022 | 43.98 Mn |